GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Capex-to-Operating-Cash-Flow

VCEL (Vericel) Capex-to-Operating-Cash-Flow : 2.15 (As of Mar. 2025)


View and export this data going back to 1997. Start your Free Trial

What is Vericel Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Vericel's Capital Expenditure for the three months ended in Mar. 2025 was $-14.21 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2025 was $6.60 Mil.

Hence, Vericel's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2025 was 2.15.


Vericel Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Vericel's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Capex-to-Operating-Cash-Flow Chart

Vericel Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.27 0.43 0.78 1.10

Vericel Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.95 0.90 1.91 0.62 2.15

Competitive Comparison of Vericel's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Vericel's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vericel's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Vericel's Capex-to-Operating-Cash-Flow falls into.


;
;

Vericel Capex-to-Operating-Cash-Flow Calculation

Vericel's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-63.974) / 58.163
=1.10

Vericel's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-14.212) / 6.6
=2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vericel  (NAS:VCEL) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Vericel Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Vericel's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Vericel Business Description

Industry
Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Executives
Dominick Colangelo director, officer: President and CEO 1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Jonathan Siegal officer: Principal Accounting Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Sean C. Flynn officer: SVP, General Counsel C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Kevin F Mclaughlin director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Zerbe Robert L Md director
Paul K Wotton director C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Mara Joseph Anthony Jr officer: Chief Financial Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Michael Halpin officer: Chief Operating Officer C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Lisa Wright director C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Sandra Pennell officer: VP and Corporate Controller C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel officer: CFO & VP , Corp. Development 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando officer: Chief Operating Officer P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino director PO BOX 376, LOBBY L., ANN ARBOR MI 48105